A Narrative Review on an Insight of Herbal Origin Drugs and Their Traditional Medicine Formulations for the Treatment of Nephrolithiasis

Year : 2024 | Volume :01 | Issue : 01 | Page : 14-30
By

Muhammad Arif

Pradeep Singh

Md Noushad Javed

Md Sabir Alam

Mohd Juned

Nisha Rajpoot

Rajendra gupta

Abstract

Ethnopharmacological relevance. There is no satisfactory treatment at present to cure or prevent kidney stone recurrences using predictable medicines. There are several marketed formulations in Ayurveda, Unani and Homeopathic Traditional Medicines (TM) have potential lithotriptic effects and clinical applications. In India, prevalence rates of complementary and alternative medicine (CAM) for the treatment of nephrolithiasis are being estimated at 63.9%. Aim of the review This review article intended to scientifically documented reports on various herbal drugs and TM formulations with ethnopharmacological and clinical relevance for the treatment of nephrolithiasis ascertain in different books, literature and research articles belonging to the Asian continent. Materials and methods This review article was prepared by utilize several review articles, original research articles and related books from constant databases, such as ScienceDirect, PubMed, Wiley Online Library, SciFinder, ACS Publications, Web of Science, Springer, and Scopus between 1980 to 2021 and the literature exploration were carry out in English. In addition, traditional applications of herbal drug and formulations for the treatment of nephrolithiasis are discussed. Results The herbal drugs and formulations discussed here are affluent in phyto-constituents resembling Phenolic and flavonoid, tri-terpenoids, alkaloids and steroids, etc., liable for the nephrolithiasis effects. A lot of information recommends that reviewed plants and their traditional formulations have valuable role in dissolving the kidney stone. Conclusions In this paper, we have reviewed the pathogenesis, risk factors and management of nephrolithiasis with numerous herbals bioactive with Ayurvedic, Unani and Homeopathic drug formulations and assess the different kinds of herbal bioactive present in formulations which are responsible for management of nephrolithiasis.

Keywords: Hajrul yahood, jawakshar, kidney stone, herbal formulation, nephrolithiasis, pashanabheda, traditional medicine

[This article belongs to International Journal of Tropical Medicines(ijtm)]

How to cite this article: Muhammad Arif, Pradeep Singh, Md Noushad Javed, Md Sabir Alam, Mohd Juned, Nisha Rajpoot, Rajendra gupta. A Narrative Review on an Insight of Herbal Origin Drugs and Their Traditional Medicine Formulations for the Treatment of Nephrolithiasis. International Journal of Tropical Medicines. 2024; 01(01):14-30.
How to cite this URL: Muhammad Arif, Pradeep Singh, Md Noushad Javed, Md Sabir Alam, Mohd Juned, Nisha Rajpoot, Rajendra gupta. A Narrative Review on an Insight of Herbal Origin Drugs and Their Traditional Medicine Formulations for the Treatment of Nephrolithiasis. International Journal of Tropical Medicines. 2024; 01(01):14-30. Available from: https://journals.stmjournals.com/ijtm/article=2024/view=144816





References

  1. Reilly, RF, 2005; Jr, Ch. 13: “Nephrolithiasis”. In Reilly Jr &Perazella, 192–207.
  2. Pak CY, et al; 1976 Nucleation and growth of brushite and calcium oxalate in urine of stone-formers. Metabolism, 25:665–73.
  3. Kok DJ, 2002; Clinical implications of physicochemistry of stone formation. Endocrinol Metab Clin North Am, 31:855–67.
  4. Carlsson P, et al; 1992; Cost effectiveness of extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy for medium-sized kidney stones: a randomised clinical trial. Scandinavian journal of urology and nephrology, 26(3):257-63.
  5. Xiao Y, et al, 2020; Sex Differences in Kidney Stone Disease in Chinese Patients with Type 2 Diabetes Mellitus. Kidney Diseases, 6(3):195-203.
  6. Hakim K, et al, 2003; Ejaz Publication House, Delhi, 2: 1201-1220.
  7. Kidney Stones in Adults, 2013; (http://www.niddk.nih.gov/health-inform ation/health-topics/urologic-disease/kidney-stones-in-adults/Pages/facts.aspx). Retrieved 22 May 2015.
  8. Miller NL, et al, 2010; In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall’s plaque. BJU int, 105:242.
  9. Miller NL, et al, 2009; A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall’s plaque. BJU Int, 103:966.
  10. Lieske JC, et al, 2006; Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int, 69:760.
  11. Taylor EN, et al, 2007; Oxalate intake and the risk for Nephrolithiasis. J Am Soc Nephro, l8:2198.
  12. Gambaro G, et al, 2004; Genetics of hypercalciuria and calcium Nephrolithiasis: from the rare monogenic to the common polygenic forms. Am J Kidney Dis, 44:963.
  13. Borghi L, et al, 2002; Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med, 346:77.
  14. Hoppe B, et al, 2005; Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis, 46:440.
  15. Borghi L, et al, 2002; Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. New England Journal of Medicine, 346(2):77-84.
  16. Domrongkitchaiporn S, et al, 2006; Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis, 48:546.
  17. Wang L, et al, 2020; A Rat Model with Multivalve Calcification Induced by Subtotal Nephrectomy and High-Phosphorus Diet. Kidney Diseases, 6(5):346-54.
  18. Allopurinol, et al, 2016; Medline Plus, National Library of Medicine, US National Institutes of Health. Retrieved 24 December,
  19. Yagisawa T, et al, 2001; Contributory metabolic factors in the development of Nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis, 37:1140.
  20. Khan MA, et al, 2012; Antiurolithic activity of Ceropegiabulbosa extract in rats: Der Pharmacia Sinica, 3:148-152.
  21. Scales CD, et al, 2012; Prevalence of kidney stones in the United States. Eur Urol, 62:160.
  22. Stamatelou KK, et al, 2003; Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int, 63:1817.
  23. Frimpong E, et al, 2018; Clinical relevance and application of traditional complementary and alternative medicine for the management of diabetes and hypertension on the African continent, 2000-2017: A narrative review. Indian J of Traditional Knowledge, 17(4):635-644.
  24. Raman S, et al, Polymeric Nanoparticles for Brain Drug Delivery-A Review. Current Drug Metabolism.
  25. Taylor EN, et al, 2009; DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol JASN, 20:2253–2259.
  26. Ferraro PM, et al, 2013; Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol CJASN, 8:1389–95.
  27. Kumar A, et al, 2020; Insights of Nanophytomedicines as a Combinatorial Therapy in Disease Diagnosis and Treatment. InNanophytomedicine (pp. 113-132). Springer, Singapore.
  28. Javed MN, et al, 2020; Pottoo FH. Recent Advancement in Clinical Application of Nanotechnological Approached Targeted Delivery of Herbal Drugs. In Nanophytomedicine (pp. 151-172), Springer, Singapore.
  29. John C. et al, 2014; New insights regarding the interrelationship of obesity, diet, physical activity, and kidney stones. Journal of the American society of nephrology, 25 (2):211-212.
  30. Bahl, et al, 1970; Advances in research in “Indian Medicine”, “Pashanbedi” drugs for urinary calculus, Udupa, K.N. (Eds), 77-98.
  31. Pottoo FH, et al, 2019; Estrogen and Serotonin: Complexity of Interactions and Implications for Epileptic Seizures and Epileptogenesis. Current neuro pharmacology, 17(3):214-31.
  32. Coe FL, et al, 1992; The pathogenesis and treatment of kidney stones. N Engl J Med, 327:1141.
  33. Al-Ali M, et al, 2003; Tribulus terrestris. Preliminary study of its diuretic and contractile effects and comparison with Zea mays. J Ethnopharmacol. 85:257–260.
  34. Shirfule AL, et al, 2011; Exploring glycolate oxidase (GOX) as an antiurolithic drug target: molecular modeling and in vitro inhibitor study. Int J Biol Macromol, 49:62–70.
  35. Matin Y, et al, 2008; Flavonoid glycosides from Tribulus terriestris L. Orientalis. Iran J Pharm Sci, 4:231–236.
  36. Shirfule AL, et al, 2011; Exploring glycolate oxidase (GOX) as an antiurolithic drug target: molecular modeling and in vitro inhibitor study. Int J Biol Macromol, 49:62–70.
  37. Shukla AK, et al, 2017; A Review on Anti-Urolithiatic Activity Of Herbal Folk Plants. Asian J of Biomaterial Res, 3(2):1-11.
  38. Saijyo J, et al, 2008; α-Glucosidase inhibitor from Bergenia ligulata. J of oleo sci. 57(8):431-5.
  39. Umashankar DC, et al, 1998; Paashaanolactone from Bergenia ligulata. Phytochemistry, 47: 907-909.
  40. Garimella TS, et al, 2001; In vitro studies on antilithiatic activity of seeds of Dolichosbiflorus Linn and rhizomes of Bergenia ligulata Wall. Phytotherapy Research 15: 351-355.
  41. Pathania S, et al, 2006; Comparative Studies of Rubiacordifolia L. and its Commercial Samples. Ethnobotanical Leaflets, 11: 179–188.
  42. Varghese G, et al, 2013; Medicinal Plants for Kidney Stone: A Monograph. Saarbrucken, Deutschland /Germany: LAP Lambert Academic Publishing. 6-109.
  43. Mahmout Y, et al, 2002; DolmazonR. Constituents of the essential oil of Cyperus maculatus Boëck. Journal of Essential Oil Research, 1; 14(4):263-5.
  44. Ram M, et al, 1997; Yield and quality of essential oil of nagarmotha (Cyperusscariosus) grown under assured water supply region of central Uttar Pradesh Pafai Journal. 19 125-127.
  45. Gilani AH et al, 1994; Hypotensive and spasmolytic activities of crude extract of Cyperusscariosus. Archives of Pharmacal Res, 17(3):145–149.
  46. Jethi R K, et al, 1983; Effect of the aqueous extract of an Ayurvedic compound preparation on mineralization & demineralization reactions, Indian J Med Res, 78: 422.
  47. Mohamed FNA, et al, 2009; Inhibition of mineralization of urinary stone forming minerals by medicinal plants. Euro J Cancer, 6(3):938–42.
  48. Iwalewa EO, et al, 2003; Analgesic, antipyretic, anti-inflammatory effects of methanol, chloroform and ether extracts of Vernonia cinerea less leaf: J Ethnopharma, 86(2–3):229–34.
  49. Gupta M, et al, 2003; Antibacterial activity of Vernonia cinerea. Fitoterapia, 74(1–2):148–50.
  50. Misra TN, et al, 1993; A New Triterpenoidal from Vernonia cinerea. Planta Med. 59(5):458-60.
  51. Bhowmik D, et al, 2012; Traditional Indian Herbs: Punarnava and Its Medicinal Importance. J of Pharmacog and Phytochem. 1 (1): 52–57.
  52. Tiwari P, et al, 2017; Antiurolithiatic effect of some polyherbal formulations used in experimentally induced urolithiasis: A review. Int. Res. J. Pharm. 8(5):14-22.
  53. Gilani AH, et al, 1993; Hepatoprotective activity of Cichoriumintybus, an indigenous medicinal plant. Medical science research. 21:151.
  54. Harsh Pal Bais, et al, 2001; Cichoriumintybus L – cultivation, processing, utility, value addition and biotechnology, with an emphasis on current status and future prospects. J of the Sci of Food and Agri. 81, 467-484.
  55. Sinha K, et al, 2004; Tinosporacordifolia (Guduchi), a reservoir plant for therapeutic applications: A Review. Indian J of Traditional Knowledge. 3(3): 257–70.
  56. Al Amin M, et al, 2012; Anti-inflammatory and analgesic activities of AsteracanthalongifoliaNees. Bangladesh Pharmaceutical J. 15(2):171-6.
  57. Schieberle P, et al, 1990; Evaluation of Potent Odorants in Cucumbers (Cucumis sativus) and Muskmelons (Cucumis melo) by Aroma Extract Dilution Analysis. J of Food Sci. 55: 193.
  58. Mackinder B, et al, 1999; Three new taxa and a new name in Dolichos L. (Leguminosae: Papilionoideae: Phaseoleae). Kew Bulletin 54(2): 415-23.
  59. Garimella TS, et al, 2001; In vitro studies on antilithiatic activity of seeds of Dolichosbiflorus Linn. And rhizomes of Berginialigulata Wall. Phytotherapy Res. 15: 315-355.
  60. Basu S, et al, 2017; Polysaccharides from Dolichosbiflorus Linn and Trachyspermumammi Linn seeds: Isolation, characterization and remarkable antimicrobial activity. Chemistry Central J. 11:118.
  61. Kawasthe, Akash, et al, 2018; Validation of Yavakshar Preparation-An Ayurvedic Alkaline Formulation. Ann of Ayur Med. 6. 115-121.
  62. Hussain IM, et al, 2016; Pathophysiology and Treatment of Urolithiasis in Unani Medicine. Indian Journal of History of Science. 51(1):217-26.
  63. Makbul SA, et al, 2018; An important mineral drug of Unani system of medicine for the management of urolithiasis. Journal of ethnopharmacology. Aug 10; 222:165-70.
  64. Rao N, et al, 2008; Evaluation of the efficacy of HajrulYahudBhasma in urolithiasis using rat as an experimental model. Indian J Pharmacol. 40:184.
  65. Faridi P, et al, 2013; Elemental analysis, physicochemical characterization and lithontriptic properties of Lapis judaicus. Pharmacognosy Journal. Mar, 5(2) :94-6.
  66. Vohora SB, et al, 2008; Mineral Drugs (used in Ayurveda and Unani medicine). Ist Ed. (English) New Delhi: Narosa Publishing House Pvt. Ltd. New Delhi; 1-90.
  67. Arayne MS, et al, 2007; The berberis story: Berberis vulgaris in therapeutics. Pharm Sci. 20: 83–92.
  68. Winston D, et al, 2011; Herbal and Nutritional Treatment of Kidney Stones, J of the Ame Herbalists Guild J A H G, Annual Symposium. 10 (2) 61-71.
  69. Varma PN, et al, 2016: A compendium of rare and clinically established mother tinctures. Dr. William Schwabe India Pvt Ltd. India. 1-95.
  70. Grieve M, 2014; A Modern Herbal. Hydrangea arborescens. Botanical.com. Retrieved p.6-30.
  71. Grieve M, 2016; A modern herbal. Courier Corporation; vol 2, Dorset Press,1-889.
  72. Hahnemann FS, 2002; Materia Medica Pura. Chronic Diseases combined and rearranged, B. Jain Publihsers, 1879, p.2.
  73. Liu H, et al, 2012; Study on chemical constituents of Lycopodium alkaloids. 37(4):475-7.
  74. Wyk, et al, 2004; Medicinal Plants of the World. Oregon, USA: Timber Press, p. 303.
  75. Sarsaparilla, et al, 2012; A Manual of Materia Medical and Pharmacology. Retrieved -04-28.
  76. Lezama V, et al, 2006; Gonzalez Ramirez Claudia: Hematopoiteic activity of Smilax aristolochiaefolia in vitro and in vivo. Pharmacologyonline. 3: 830–838.
  77. Siddiqui VA, et al, 2019; A multicentre observational study to ascertain the role of homoeopathic therapy in Urolithiasis.Indian Journal of Research in Homoeopathy, 5(2), 30-39.
  78. William B, et al, 2007; Boericke’s New Manual of Homoeopathic Materia medica, 3rd revised and augmented edition. New Delhi; B. Jain Publishers Pvt. Ltd. p. 147.
  79. Atmani F, et al, 2004; Extract from Herniaria hirsute coats calcium oxalate monohydrate crystals and blocks their adhesion to renal epithelial cells. J. Urol., 172: 1510 -1514.
  80. Al-Snafi, 2018; Pharmacological Importance of Herniaria glabra and HerniariahirsutaA Review, Indo Am. J. P. Sci, 05(04) 2167-2175.
  81. Günaydin K, et al, 2004; The chemical investigations on the ripe fruits of Ammi visnaga (Lam.) Lamarck growing in Turkey. Nat Prod Res. 18:169–75.
  82. Bhagavathula AS, et al, 2015; Ammi Visnaga in treatment of urolithiasis and hypertriglyceridemia. Pharmacog Res. 7(4): 397-400.
  83. Kooti W, et al, 2015; A review on medicinal plant of Apium graveolens. Advanced Herbal Medicine. 1(1):48-59.
  84. Fazal SS, et al, 2012; Review on the pharmacognostical & pharmacological characterization of Apium graveolens Linn. Indo Global Journal of Pharmaceutical Sciences. 2(1):36-42.
  85. Erickson SB, et al, 2011; Effect of Cystone® on urinary composition and stone formation over a one-year period. Phytomedicine. Jul 15; 18(10):863-7.
  86. Jayaramaiah KK, et al, 2013; a well-known herbal formulation, inhibits struvite crystal growth formation in single diffusion gel growth technique. Journal of Experimental & Integrative Medicine. Jan 1; 3(1).
  87. Vidyashankar S, et al, 2010; Cystone–An ayurvedic polyherbal formulation inhibits adherence of uropathogenic E. coli and modulates H2O2-induced toxicity in NRK-52E cells. Journal of Experimental Pharmacology. 2: 1-19.
  88. Goyal PK, et al, 2017; Antiurolithiatic potential of neeri against calcium-oxalate stones by crystallization inhibition, free radicals scavenging, and NRK-52E cell protection from oxalate injury. Pharmacognosy Magazine. Oct; 13(Suppl 3):S549.
  89. Sharma AK, et al, 2016; Nephroprotective role of neeri-kft (a polyherbal formulation) against gentamicin induced nephrotoxicity in experimental rat model: a preclinical study. European J Pharm Med Research 3(8):410-417.
  90. Dixit P, et al, 2014; Anti-urolithiatic Activity of crashcal on Ethylene Glycol Induced urolithiasis in Rats. RGUHS J Pharm Sci. 4(1):30-35.
  91. Roy A, et al, 2012; Evaluation of efficacy and safety of Renomet, a polyherbal formulation in the treatment of urolithiasis: A double blind randomized study. International Journal of Pharmaceutical Sciences and Drug Research; 4(2):130-3.
  92. Thakkar T, et al, 2013; Evaluation of acute toxicity study and diuretic activity of Ural syrup. Int j of res in Ayur and Phar, 4(4): 522-525.
  93. Jarald EE, et al, 2011; Effect of Unex on ethylene glycol-induced urolithiasis in rats. Indian journal of pharmacology. Jul; 43(4):466-468.
  94. indiamart.com/satyamhealthcare/kidney-stone-removal-medicine.html
  95. Lulat SI, et al, 2016; Antiurolithiatic effect of lithocare against ethylene glycol-induced urolithiasis in Wistar rats. Indian journal of pharmacology. Jan; 48(1):78-82.
  96. Singh RG, et al; Litholytic property of Kulattha (Dolichous biflorus) vs potassium citrate in renal calculus disease: a comparative study. JAPI. 2010 May; 58:287.
  97. Singh I, et al, 2011; Prospective randomized clinical trial comparing phytotherapy with potassium citrate in management of minimal burden nephrolithiasis. Urology Annals. May; 3(2):75.
  98. Qadir A, et al, 2018; Chemical composition of Saudi Arabian Sukkari variety of date seed oil and extracts obtained by slow pyrolysis. Indian Journal of Pharmaceutical Sciences. Oct 30; 80(5):940-6..
  99. Kamal M, et al, 2017; Adaptogenic medicinal plants utilized for strengthening the power of resistance during chemotherapy–a review. Oriental Pharmacy and Experimental Medicine. Mar 1; 17(1):1-8.
  100. Sharma S, et al, 2020; Ameliorative effect of a standardized polyherbal combination in methotrexate-induced nephrotoxicity in the rat. Pharmaceutical Biology. Jan 1; 58(1):184-99.
  101. Kamal M, et al, 2019; Natural products and their active principles used in the treatment of neurodegenerative diseases: a review. Oriental Pharmacy and Experimental Medicine. Dec; 19(4):343-65.
  102. Pandey M, et al, 2020; PINK1/Parkin in Neurodegenerative Disorders: Crosstalk between Mitochondrial Stress and Neurodegeneration. In Quality Control of Cellular Protein in Neurodegenerative disorders. 282-301.
  103. Mohanta BC, et al, 2020; Polyelectrolyte complexes of alginate for controlling drug release. In Alginates in Drug Delivery Jan 1 (pp. 297-321). Academic Press.
  104. Pottoo FH, et al, 2020; Raloxifene potentiates the effect of fluoxetine against maximal electroshock induced seizures in mice. European Journal of Pharmaceutical Sciences. 146:105261.
  105. Singh P, et al, 2020; Simultaneous analytical efficiency evaluation using HPTLC method for analysis of syringicacid and vanillic acid and their anti-oxidant capacity from methanol extract of Ricinus communis Linn. and Euphorbia hirta Linn. Journal of AOAC International. Dec. DOI: 10.1093/jaoacint/qsaa171.
  106. Arif M, et al, 2016; Stress relaxant and antioxidant activities of acid glycoside from Spondiasmangifera fruit against physically and chemically challenged albino mice. Journal of pharmacy & bioallied sciences. 8(1):58.

Regular Issue Subscription Review Article
Volume 01
Issue 01
Received March 8, 2024
Accepted March 12, 2024
Published May 2, 2024